Fall 2011 (Vol. 28, No. 3)

A Message from the President

2011 has been an extraordinary year for melanoma treatments, with the introduction of not one but two new life-extending melanoma drugs. In March, as reported in the Spring 2011 issue of Sun & Skin News, the US Food and Drug Administration (FDA) approved YervoyTM (ipilimumab), the first new melanoma drug in 13 years. The availability of any new treatment for melanoma, which will cause an estimated 8,790 deaths in the US this year alone, is exciting. But YervoyTM has garnered particular enthusiasm: it is the first therapy proven to extend overall survival for patients with advanced disease. Many patients treated with YervoyTM may have a two-year survival advantage, and a smaller percentage may be virtually cured.

Read More

Sun & Skin News: Fall 2011 (Vol. 28, No. 3)